RxDoctor Payments Data

Eric Kirschner, MD

Cardiovascular Disease · New York, NYNPI 1902953490

Payments from drug & device makers

$1,387in general payments, 2019–2025

Across 79 payments — averaging $17.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$358
  • GSK$184
  • Pfizer$116
  • Amgen$84
  • Amarin Pharma, Inc.$70
  • Takeda Pharmaceuticals U.S.A., Inc.$70
  • plus $505 from 20 others

What the payments were for

  • Food & beverage$1,387100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,387 in reported general payments places this provider in the 45th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$123,115
Medicare patients
359
Services billed
1,471

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban69$94,853
EliquisApixaban91$94,707
JardianceEmpagliflozin15$22,402
JanuviaSitagliptin Phosphate34$21,273
EntrestoSacubitril/Valsartan14$21,141
Atorvastatin Calcium398$3,522
Losartan Potassium286$3,045
Metoprolol Succinate132$1,789
SynthroidLevothyroxine Sodium21$1,320
Amlodipine Besylate200$1,272
Ezetimibe46$1,110
Levothyroxine Sodium90$1,089
Rosuvastatin Calcium82$967
Omeprazole68$939
Hydrochlorothiazide143$908

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$65$94,85369 claims
PfizerEliquis$116$94,70791 claims
MerckJanuvia$12$21,27334 claims
NovartisEntresto$25$21,14114 claims
AbbVieSynthroid$11$1,32021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →